Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used...

Full description

Bibliographic Details
Main Authors: Aline Baldo, Amaya Leunda, Nicolas Willemarck, Katia Pauwels
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
recombinant viral vector vaccines
environmental risk assessment
vaccination
biosafety
Online Access:https://www.mdpi.com/2076-393X/9/5/453

Similar Items

Similar Items